MX2024004714A - Nuevas sales de trimetazidina. - Google Patents

Nuevas sales de trimetazidina.

Info

Publication number
MX2024004714A
MX2024004714A MX2024004714A MX2024004714A MX2024004714A MX 2024004714 A MX2024004714 A MX 2024004714A MX 2024004714 A MX2024004714 A MX 2024004714A MX 2024004714 A MX2024004714 A MX 2024004714A MX 2024004714 A MX2024004714 A MX 2024004714A
Authority
MX
Mexico
Prior art keywords
trimetazidine
salts
novel
nitrites
result
Prior art date
Application number
MX2024004714A
Other languages
English (en)
Spanish (es)
Inventor
Frédéric Villard
Julien Mahieux
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2024004714A publication Critical patent/MX2024004714A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004714A 2021-10-20 2022-10-19 Nuevas sales de trimetazidina. MX2024004714A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21306465 2021-10-20
PCT/EP2022/079054 WO2023066971A1 (en) 2021-10-20 2022-10-19 Novel trimetazidine salts

Publications (1)

Publication Number Publication Date
MX2024004714A true MX2024004714A (es) 2024-05-10

Family

ID=78592764

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004714A MX2024004714A (es) 2021-10-20 2022-10-19 Nuevas sales de trimetazidina.

Country Status (20)

Country Link
US (1) US20250250245A1 (enExample)
EP (1) EP4419510B1 (enExample)
JP (1) JP2024539090A (enExample)
KR (1) KR20240093576A (enExample)
CN (1) CN118076591A (enExample)
AR (1) AR127403A1 (enExample)
AU (1) AU2022369026A1 (enExample)
CR (1) CR20240157A (enExample)
DK (1) DK4419510T3 (enExample)
ES (1) ES3057370T3 (enExample)
HR (1) HRP20251413T1 (enExample)
IL (1) IL311916A (enExample)
LT (1) LT4419510T (enExample)
MA (1) MA66951B1 (enExample)
MX (1) MX2024004714A (enExample)
PL (1) PL4419510T3 (enExample)
PT (1) PT4419510T (enExample)
RS (1) RS67449B1 (enExample)
SI (1) SI4419510T1 (enExample)
WO (1) WO2023066971A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106477A1 (en) * 2023-11-14 2025-05-22 Samsara Therapeutics Inc. Novel autophagy inducing compounds and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104138376A (zh) * 2013-05-06 2014-11-12 常州高新技术产业开发区三维工业技术研究所有限公司 一种提高缺氧耐受力的缓释剂
FR3027803B1 (fr) 2014-11-05 2018-02-09 Les Laboratoires Servier Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion
CN105287564A (zh) * 2015-09-06 2016-02-03 余祖江 一种防治肝病的西药复合物及其用途
CN110183398B (zh) 2019-05-14 2021-06-29 中南民族大学 一种曲美他嗪草酸盐及其制备方法和应用
CN110105307B (zh) 2019-05-14 2021-06-01 中南民族大学 一种曲美他嗪草酸盐及其制备方法和应用
CN110054599B (zh) * 2019-05-14 2021-05-07 中南民族大学 一种曲美他嗪草酸盐及其制备方法和应用
CN112043691A (zh) * 2019-06-06 2020-12-08 常州高新技术产业开发区三维工业技术研究所有限公司 一种药物组合物及其用途

Also Published As

Publication number Publication date
IL311916A (en) 2024-06-01
CR20240157A (es) 2024-05-22
EP4419510B1 (en) 2025-10-08
ES3057370T3 (en) 2026-03-02
WO2023066971A1 (en) 2023-04-27
JP2024539090A (ja) 2024-10-28
LT4419510T (lt) 2025-12-29
CN118076591A (zh) 2024-05-24
CA3234743A1 (en) 2023-04-27
US20250250245A1 (en) 2025-08-07
RS67449B1 (sr) 2025-12-31
AR127403A1 (es) 2024-01-17
KR20240093576A (ko) 2024-06-24
EP4419510A1 (en) 2024-08-28
HRP20251413T1 (hr) 2025-12-19
MA66951B1 (fr) 2025-12-31
AU2022369026A1 (en) 2024-05-02
PT4419510T (pt) 2026-01-02
SI4419510T1 (sl) 2026-01-30
DK4419510T3 (da) 2025-11-17
PL4419510T3 (pl) 2026-02-16

Similar Documents

Publication Publication Date Title
MX2022010040A (es) Compuestos moduladores de gcn2.
CL2019002869A1 (es) Inhibidores selectivos hdac6.
CL2024003156A1 (es) Proceso e intermedios para preparar un inhibidor de jak1
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
CL2017000368A1 (es) Compuestos fusionados de 11 miembros y fungicidas agrícolas/hortícolas que los contienen
MX2019011496A (es) Composiciones de niraparib.
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
MX2023014281A (es) Lipidos novedosos.
AR105967A1 (es) Sales de un inhibidor de pim quinasa
MX379400B (es) Combinaciones novedosas de un antagonista de h3 y un inhibidor de recaptacion de noradrenalina y sus usos terapéuticos.
MX2025003091A (es) Metodo para producir derivado de heterociclideno acetamida
MX373659B (es) Metodo para producir un pentapeptido sintetico.
PE20221009A1 (es) Sintesis de un inhibidor de calicreina plasmatica a escala de proceso
CR20240157A (es) Nuevas sales de trimetazidina
MX2018013515A (es) Una composicion antimicrobiana topica.
AR116951A1 (es) Sales cristalinas de un inhibidor de calicreína plasmática
CO2022011862A2 (es) Proceso para la preparacion de compuestos de antranilamida artropodicida
CL2022001511A1 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina
CO2026001216A2 (es) Composición agroquímica
PE20181194A1 (es) Solucion acuosa de peroxido de hidrogeno que comprende un estabilizante especifico
UY39656A (es) Proceso para producir una composición herbicida liquida.
MX2025012408A (es) Nuevas fases solidas de trimetazidina
MX2021010613A (es) Procedimiento para la preparacion de 4-amino-5-metilpiridona.
MX2022000651A (es) Proceso mejorado para preparar ozanimod.
CL2019000294A1 (es) Síntesis de (s)-2-amino-4-metil-1-((r)-2-metiloxirano-2-il)-pentan-1-ona y sales farmacéuticamente aceptables de la misma.